Abbott Laboratories reported $46.6B of revenue over the trailing twelve months, +8.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $46.6B (to Q2 2026). Net income: $5.42B, trailing twelve months to Q2 2026. Free cash flow: $7.82B, trailing twelve months to Q2 2026. Operating margin: 16%, trailing twelve months to Q2 2026.

ABTAbbott Laboratories

Healthcare

$103.70-18% 1Y

$103.70

$82.5652 weeks$129.12

ABT as reported

Abbott Laboratories reported $46.6B of revenue over the trailing twelve months, +8.1% on the year before. 11 reported series are charted on this page, each one as filed.

$46.6B

Revenue, trailing twelve months · to Q2 2026 · +8.1% against the twelve months before

Net income: $5.42B
Net income · −61% year on year · trailing twelve months to Q2 2026
Free cash flow: $7.82B
Free cash flow · +15% year on year · trailing twelve months to Q2 2026
Operating margin: 16%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ABT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$46.6B	+8.1%	Q2 2026
Net income	$5.42B	−61%	Q2 2026
EPS	$3.10	−61%	Q2 2026
Gross margin	57%	n/a	Q2 2026
Operating margin	16%	n/a	Q2 2026
Net margin	12%	n/a	Q2 2026
ROE	16%	n/a	Q2 2026
ROA	8.7%	n/a	Q2 2026
ROIC	9.3%	n/a	Q2 2026
Free cash flow	$7.82B	+15%	Q2 2026
P/E	33.5	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.